丽珠医药集团股份有限公司（以下简称"公司"）于 2022 年 10 月 25 日召 开了公司 2022 年第三次临时股东大会、2022 年第三次 A 股类别股东会及 2022 年第三次 H 股类别股东会，审议通过了《关于回购公司部分 A 股股份方案的议 案》，同意公司以不低于人民币 40,000 万元（含），不超过人民币 80,000 万元 （含）的回购总金额，及不超过人民币 40.00 元/股的回购价格，回购公司部分 A 股股份，用于注销减少注册资本，有关详情请见公司于 2022 年 10 月 26 日发布 的《丽珠医药集团股份有限公司回购报告书》（公告编号：2022-072）。现将公 司回购股份的进展情况公告如下： 截至 2023 年 8 月 31 日，公司通过集中竞价交易方式回购了公司 A 股股份 共计 6,492,548 股，占公司总股本的比例为 0.67%，购买的最高价为人民币 35.50 元/股，最低价为人民币 32.25 元/股，已使用的资金总额为人民币 220,548,615.22 元（不含交易费用）。上述回购符合公司既定的回购股份方案。 后续公司将根据实施回购股份的进展情况，严格按照《深圳证 ...

Financial Performance - Livzon Pharmaceutical reported a revenue of RMB 6,689.92 million for the first half of 2023, representing a 6.15% increase compared to the same period in 2022[15]. - The net profit attributable to shareholders was RMB 1,227.31 million, reflecting a decrease of 13.96% year-over-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to RMB 1.09 in the previous year[16]. - Livzon Pharmaceutical's cash flow from operating activities was RMB 1,423.37 million, showing a 6.15% increase from the previous year[15]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 1,093.71 million, up 4.52% from RMB 1,046.42 million in the same period last year[43]. - The company reported a total income tax expense of RMB 249.30 million, which is a 21.57% increase year-on-year, primarily due to higher taxable income[76]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue[16]. - The revenue from biological products increased by 14.26% to RMB 953.85 million[16]. - The revenue from traditional Chinese medicine preparations reached RMB 953.85 million, a year-on-year increase of 94.42%, accounting for 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment was RMB 297.99 million, a year-on-year decrease of 13.88%, representing 4.45% of the total revenue[58]. - The revenue from APIs and intermediates was RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from chemical agents was RMB 3,480.29 million, a year-on-year decrease of 2.42%, accounting for 52.02% of the total revenue[45]. - The revenue from biological products was RMB 113.41 million, a year-on-year increase of 5.93%, accounting for 1.70% of the total revenue[51]. Strategic Initiatives - The company is focusing on new product development and market expansion strategies to enhance growth prospects[18]. - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[30]. - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for chronic diseases[30]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[30]. - The company is actively pursuing international cooperation and licensing for its innovative products and pipelines, with ongoing discussions with multiple international partners[60]. - The company has achieved a strategic partnership with leading global pharmaceutical companies, enhancing its market position[54]. Research and Development - The company has made significant progress in the development of new drugs, including the approval of the injection of leuprolide acetate microspheres for prostate cancer[46]. - The company has registered 20 products in 11 overseas countries/regions as of the end of the reporting period[49]. - The company has completed 135 international registration projects for APIs and intermediates in 63 overseas countries/regions[55]. - The company has nine ongoing research projects in traditional Chinese medicine, with the SXSHL gel completing preclinical studies and the TGDX granules finishing clinical trials[57]. - The company has 7 ongoing research projects for complex formulations, with 1 approved for market and 1 completing Phase III clinical trials[79]. - A total of 27 key projects are under research, with 3 approved for market and 4 in the production application stage[80]. - In the biopharmaceutical sector, there are 8 ongoing projects, with 2 approved for market and 1 approved for emergency use[81]. Market Expansion and Sales - User data indicates a growth in customer base by 25%, with over 5 million active users engaging with the company's products[30]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2023, reflecting a growth rate of 18%[30]. - The company plans to strengthen its marketing efforts in traditional Chinese medicine, focusing on the sales of specific products like the Qishi Fuzheng injection in oncology and expanding into pediatric and geriatric medicine[182]. - The company aims to improve its supply chain efficiency and strengthen quality management to prevent major quality safety incidents[177]. - The company will continue to focus on the research, production, and sales of pharmaceutical products, including various formulations and active pharmaceutical ingredients[42]. Financial Position and Liabilities - The total assets increased by 3.46% to RMB 25,726.13 million from RMB 24,864.83 million at the beginning of the period[42]. - Total liabilities rose by 15.59% to RMB 11,476.30 million from RMB 9,928.57 million at the beginning of the period[42]. - The asset-liability ratio rose from 39.93% to 44.61% as of June 30, 2023, indicating a higher level of debt relative to assets[94]. - The company's long-term borrowings rose by 32.81% to RMB 2,622,263,438.94, primarily due to new bank loans[92]. - The group’s total borrowings amounted to RMB 4,232.26 million as of June 30, 2023, up from RMB 3,596.68 million as of December 31, 2022, representing 16.45% of total assets[105]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with expected annual investments over the next five years[145]. - The company has committed to using the raised funds for specific projects, including the development of innovative products and technology upgrades, aligning with its strategic goals[141]. - The company has reported a significant increase in investment amounting to RMB 727,085,150.00 for the current period, compared to RMB 30,000,065.77 in the previous period, reflecting a change of 2,323.61%[123]. - The company has allocated RMB 51,685.32 million for replenishing working capital and repaying bank loans, achieving 100% of the planned investment[154]. Risk Management and Compliance - The company has implemented a foreign exchange risk management system to mitigate the impact of currency fluctuations on its business[112]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational capabilities in response to evolving regulations[185]. - The company has established risk management measures to mitigate market, operational, and legal risks associated with derivative investments[136]. - The company aims to enhance its operational efficiency through improved risk management practices in derivative trading[136]. Sustainability and Environmental Initiatives - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[195]. - The company has established GAP production bases for key traditional Chinese medicine raw materials to mitigate supply risks[194]. - The company aims to establish a green ecological planting base for key medicinal materials to support its core product research and development[182].

翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2023年8月25日 FF304 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 A | | 於香港聯交所上市(註11) | 否 | | | 證券代號 (如於香港聯交所上市) | | | 說明 | | | | | | 發行股份 | (註6及7) | | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | | 2023年8月7日 | 625,721,470 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | | 258,000 | 0.02758 % | | | % | | 於2023年8 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-072 丽珠医药集团股份有限公司关于 注射用醋酸曲普瑞林微球新适应症上市许可申请获受理的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，丽珠医药集团股份有限公司（以下简称"本公司"）及控股子公司上 海丽珠制药有限公司收到国家药品监督管理局核准签发的《受理通知书》（受理 号：CXHS2300072），受理注射用醋酸曲普瑞林微球子宫内膜异位症注册上市 许可的申请。现将有关详情公告如下： 一、受理通知书主要内容 药品通用名称：注射用醋酸曲普瑞林微球 英文名：Triptorelin Acetate Microspheres for Injection 剂型：注射剂 规格：3.75mg（按 C64H82N18O13计） 申请事项：境内生产药品注册上市许可 注册分类：化学药品 2.4 类 受理通知书审批结论：根据《中华人民共和国行政许可法》第三十二条的规 定，经审查，决定予以受理。 二、药品的相关情况 注射用醋酸曲普瑞林微球是本公司自主开发的高端长效微球制剂，已于2023 年5 ...

Financial Performance - Livzon Pharmaceutical Group reported a revenue increase of 15% year-on-year for the first half of 2023, reaching approximately RMB 1.2 billion[1]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2023, representing a growth of 12%[1]. - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion, representing a year-over-year growth of 25%[12]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[23]. - The company’s revenue from domestic operations was RMB 5,837,038,944.67, which is 87.25% of total revenue, reflecting a year-on-year increase of 7.15%[40]. - Total revenue for the period was RMB 6,689,918,114.87, compared to RMB 6,302,565,210.60 in the previous period, marking an increase of 6.15%[42]. - The company reported a net profit margin of 18% for the first half of 2023, up from 15% in the same period last year[1]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[23]. - The company reported a net profit of approximately RMB 393.59 million for the period, with total revenue reaching RMB 1.72 billion, reflecting a strong performance in the pharmaceutical sector[96]. Research and Development - The company plans to invest 10% of its revenue into R&D for new products and technologies in the upcoming fiscal year[1]. - The company is investing in R&D, allocating RMB 200 million for the development of new technologies and products[12]. - R&D expenses amounted to RMB 610,783,249.63, a 10.15% increase from RMB 554,519,983.73 in the previous period[46]. - The company is committed to innovation in drug development, focusing on unmet clinical needs and high-barrier complex formulations, while enhancing its R&D capabilities[111]. - The company is committed to advancing its biopharmaceutical projects, including the clinical trials for key products like recombinant human IL-17A/F monoclonal antibody injection and recombinant human follicle-stimulating hormone injection[104]. Market Expansion - Livzon is focusing on market expansion in Southeast Asia, targeting a 30% increase in market share by the end of 2024[1]. - Market expansion efforts include entering two new international markets, which are projected to generate an additional RMB 500 million in revenue[12]. - The company is focusing on expanding its international market presence, particularly in countries such as Pakistan, Indonesia, and Uzbekistan, for its reproductive, digestive, and antiviral products[24]. - The company is actively exploring partnerships with international firms to enhance its global presence and distribution channels[1]. Product Development - Livzon has launched two new products in the cardiovascular segment, contributing to a 25% increase in sales in that category[1]. - New product launches are expected to contribute an additional RMB 300 million in revenue over the next fiscal year[12]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials to strengthen the integration of raw materials and formulations[35]. - The company is investing in the development of new traditional Chinese medicine products and classic formulas, aiming to accelerate R&D progress in this area[106]. Financial Management - The company has identified potential risks related to regulatory changes and is developing strategies to mitigate these risks[1]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management[12]. - The total cost of sales for the period was RMB 2,402,469,642.77, up from RMB 2,191,804,060.15, reflecting a growth of 9.62%[42]. - The company’s cash flow from operating activities decreased by 13.96%, amounting to RMB 1,227.31 million compared to RMB 1,426.39 million in the previous period[23]. Employee and Talent Management - The company has developed a talent assessment system to enhance internal talent selection and training, with 23 training programs planned for 2023[76]. - Employee training initiatives have seen high participation and satisfaction rates, aligning with local government initiatives to strengthen the talent pool[77]. - The company has 8,649 employees, a decrease from 9,005 employees as of December 31, 2022[76]. - Total employee compensation for the reporting period was RMB 859.95 million, up from RMB 844.02 million in the previous period, reflecting a year-over-year increase[76]. Environmental and Sustainability Initiatives - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by 20% over the next three years[12]. - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[113]. - The company has faced increasing environmental compliance costs due to stricter regulations, necessitating further investment in environmental protection measures[113]. - The company has maintained a zero exceedance record for pollutant emissions, adhering to the standards set by Jiangyin wastewater treatment plant[198]. Corporate Governance - The company has adhered to the Corporate Governance Code from January 1, 2023, to June 30, 2023, in compliance with the Hong Kong Listing Rules[186]. - The board consists of 11 members, including 2 executive directors, 4 non-executive directors, and 5 independent non-executive directors[183]. - The company held a temporary shareholders' meeting on January 10, 2023, with a participation rate of 7.01% to approve the establishment of a joint venture with the controlling shareholder[184]. Strategic Investments - The company is considering strategic acquisitions to enhance its market position, with a budget of up to RMB 1 billion for potential targets[12]. - The company made significant equity investments, including RMB 600 million for a 60% stake in Wuhan Kanglijian Health Investment Management Co., and RMB 102 million for a 51% stake in Lijian (Guangdong) Animal Health Co.[80]. - The company has approved the continuation of the "Lijuzhou Group New Beijiang Pharmaceutical Co., Ltd. relocation and expansion project (Phase I)" after re-evaluating the project that had been on hold for over a year[119].

Financial Performance - The company's operating revenue for the six months ended June 30, 2023, was RMB 6,689.92 million, representing a 6.15% increase compared to the same period last year[15]. - The net profit attributable to shareholders for the same period was RMB 1,227.31 million, reflecting a decrease of 13.96% year-on-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to the previous period[16]. - The company reported a net cash flow from operating activities of RMB 1,046.42 million, which is a 4.52% increase from the previous year[15]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[30]. - The company achieved operating revenue of RMB 6,689.92 million in the first half of 2023, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - The net profit attributable to shareholders reached RMB 1,134.57 million, reflecting a year-on-year growth of 11.50% from RMB 1,017.55 million[43]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue, with a growth of 26.63%[16]. - The revenue from biological products was RMB 1,781.67 million, showing a growth of 14.26% year-on-year[16]. - The revenue from the raw materials and intermediates segment reached RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from the Chinese medicine preparation segment reported revenue of RMB 953.85 million, a significant year-on-year growth of 94.42%, representing 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment decreased to RMB 297.99 million, a decline of 13.88%, making up 4.45% of the total revenue[58]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings[18]. - Market expansion plans include entering two new international markets by Q4 2023, aiming for a 5% market share in each[30]. - The company actively expanded its international market presence, focusing on product registration in countries such as Pakistan, Indonesia, and Uzbekistan, with 20 product specifications registered in 11 overseas countries/regions[49]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[30]. Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for new drug development initiatives[30]. - The company is enhancing its R&D capabilities and international collaboration to strengthen its competitive edge in various therapeutic areas[63]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials and formulations integration[64]. - The company is advancing key projects in the field of biological products, including the approval of the recombinant human chorionic gonadotropin injection for overseas registration in Tajikistan and ongoing submissions in other countries[51]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[30]. - The company has implemented new technologies in production, resulting in a 30% increase in efficiency[30]. - The company is enhancing its production and quality management systems to improve product delivery capabilities and reduce operational costs through lean production initiatives[48]. - The company has implemented measures to improve operational efficiency and safety awareness among employees through training programs[61]. Financial Position and Liabilities - Total assets at the end of the period were RMB 25,726,127,198.95, representing a 3.46% increase from RMB 24,864,825,366.23 at the beginning of the period[36]. - Total liabilities increased by 15.59%, reaching RMB 11,476,301,953.22 compared to RMB 9,928,573,774.51 at the beginning of the period[36]. - The company's asset-liability ratio rose from 39.93% as of December 31, 2022, to 44.61% as of June 30, 2023[94]. - Long-term borrowings increased by 32.81% to RMB 2,622,263,438.94, attributed to new bank loans[93]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company made significant investments totaling RMB 727,085,150.00 during the reporting period, a 2,323.61% increase compared to the previous period's investment of RMB 30,000,065.77[123]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with an expected completion date by December 31, 2020[145]. - The company has committed to using the raised funds for various projects, including the development of innovative products and technology platforms, in line with its strategic goals[141]. Compliance and Risk Management - The company has established risk control measures to mitigate market, operational, and legal risks associated with derivatives trading[136]. - The company emphasizes the importance of regulatory compliance and environmental management, increasing investments in environmental protection equipment[195]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational systems in response to evolving regulations[186]. Future Outlook - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[30]. - The company plans to enhance its R&D efficiency and strengthen its innovative drug and complex formulation platforms in the second half of 2023[176]. - The company aims to deepen its market presence in key disease areas such as autoimmune diseases and respiratory infections through targeted sales management[183].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 中國，珠海 二零二三年八月十四日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本公司的非執行董 事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、邱慶豐先生及俞雄先生 ; 而本公司的獨立非執行董事為白 華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗婕女士。 * 僅供識別 1 香港主要營業地點 所在大廈名稱變更 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* （「本公司」）董事會（「董事會」） 宣佈，由於大廈名稱變更，本公司於香港的主要營業地點之大廈名稱由「中國恒大中心」更改為「萬 通保險中心」。據此，本公司於香港的主要營業地點地址變更為香港灣仔告士打道38號萬通保險中 心13樓1301室，自二零二三年八月十四日起生效。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmac ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-067 关于布南色林片获得注册批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，丽珠医药集团股份有限公司（以下简称"本公司"）全资子公司丽珠 集团丽珠制药厂收到国家药品监督管理局核准签发的《药品注册证书》（证书编 号：2023S01273），布南色林片获批上市。现将相关情况公告如下： 一、药品注册证书主要内容 药品名称：布南色林片 英文名/拉丁名：Blonanserin Tablets 剂型：片剂 规格：4mg 申请事项：药品注册（境内生产） 丽珠医药集团股份有限公司 注册分类：化药 4 类 上市许可持有人：丽珠集团丽珠制药厂 生产企业：丽珠集团丽珠制药厂 药品批准文号：国药准字 H20234039 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关情况 布南色林片于 2022 年 2 月递交上市申请，受理号为：CYHS2200460。布南 色林片适应症为：用于治疗精神分 ...

丽珠医药集团股份有限公司投资者关系活动记录表 编号：2023-11 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 √现场参观 √其他：主题投教活动——走进上市公司 丽珠集团——副总裁、董事会秘书 杨亮 丽珠集团——投资者关系总监 陈文霞 丽珠集团——证券事务代表 叶德隆 财通证券——分析师 赵则芬 招商基金——投资经理 邹俊之 活动参与人员 招商基金——基金经理 吴德瑄 招商基金——基金经理 蔡宇滨 招商基金——研究员 宋歌 华泰证券广东分公司、中山市中山五路营业部，个人投资 者 17 人 时间 8 月 2 日 13:30-14:30 8 月 9 日 14:30-16:30 地点 本公司总部大楼、办公室 形式 线上参会、现场调研 1、参观展厅 2、交流&问答环节 问：简单介绍丽珠的投资亮点。 交流内容及具体问答 首先是可持续的业绩稳健增长。公司拥有多元化的业 记录 务布局、丰富的在销与在研产品管线、持续的管理与经营 创新，积极应对过去近十年来的行业变化及挑战。过去十 年，公司实现了在化药、生物药、中药、原料药、试剂领 域的平衡布局，各业务端都保持自身的特 ...

丽珠医药集团股份有限公司投资者关系活动记录表 编号：2023-10 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 丽珠集团——副总裁、董事会秘书 杨亮 华泰证券——首席分析师 代雯 华泰证券——分析师 沈卢庆 银华基金——研究员 岳梅梅 平安养老——研究员 陶歆蔚 鹏扬基金——研究员 王雪刚 璟恒投资——基金经理 李育慧 Oberweis——研究员 Fangwen Zhou 玄甲投资——基金经理 林佳义 煜德基金——研究员 蔡苗 敦和资产——研究员 叶施 活动参与人员 宽远资产——研究员 李韵滢 趣时资产——研究员 王晓东 China Galaxy——基金经理 刘颖 相聚资本——研究员 邓巧 Capital Group——研究员 陈婉 汇丰前海证券——医药行业主管 舒影岚 汇丰前海证券——医药分析师 柴欣然 摩根斯坦利基金——基金经理 王大鹏 摩根斯坦利基金——基金经理 赵伟捷 摩根斯坦利基金——医药分析师 潘海洋 摩根斯坦利基金——实习生 李昂 摩根斯坦利基金——实习生 周佳诚 | --- | --- | |------------ ...